Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival

BACKGROUND: Radioimmunotherapy (RIT) has been used to treat relapsed/refractory CD20+ Non-Hodgkin lymphoma (NHL). Myeloablative anti-CD20 RIT followed by autologous stem cell infusion (ASCT) enables high radiation doses to lymphoma sites. We performed a phase I/II trial to assess feasibility and sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Julia Y, Schwarz, Kathleen, Schreiber, Susanne, Schmidt, Burkhard, Wester, Hans-Jürgen, Schwaiger, Markus, Peschel, Christian, von Schilling, Christoph, Scheidhauer, Klemens, Keller, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757247/
https://www.ncbi.nlm.nih.gov/pubmed/23765188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757247/
https://www.ncbi.nlm.nih.gov/pubmed/23765188

Ejemplares similares